GlassScriptPhysician profile
John J Haluschak
NPI 1407895535
$8,946.64
in general payments reported to CMS, 2019-2025
40 companies · $27.25 in 2025
The $27.25 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $1,956 · 2021: $1,248 · 2022: $576 · 2023: $4,323 · 2024: $544 · 2025: $27.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,220 · Food and Beverage: $1,952 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $450 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,220.00 |
| Food and Beverage | $1,951.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $450.00 |
| Education | $272.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,740.72 | 2020-2023 | Lynparza, Imfinzi |
| Pfizer INC. | $983.48 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $250.33 | 2021-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $226.44 | 2019-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $206.90 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $201.29 | 2019-2023 | |
| Amgen INC. | $193.97 | 2022-2023 | Lumakras, Xgeva, Vectibix |
| Glaxosmithkline, LLC. | $154.75 | 2023-2024 | Ojjaara, Shingrix |
| Sanofi-Aventis U.S. LLC | $154.50 | 2023 | |
| Janssen Biotech, INC. | $153.12 | 2019-2023 | Erleada, Balversa |
| Rigel Pharmaceuticals, INC. | $151.62 | 2022-2023 | Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $144.51 | 2022 | |
| Merck Sharp & Dohme LLC | $144.49 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Blueprint Medicines Corporation | $140.04 | 2023 | Ayvakit |
| Cti Biopharma Corp. | $138.89 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $124.99 | 2021 | |
| Agios Pharmaceuticals, INC. | $124.98 | 2024 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $110.30 | 2023-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $72.82 | 2019-2023 | |
| Genzyme Corporation | $54.85 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $52.49 | 2023 | Provenge |
| Array Biopharma INC | $45.75 | 2022-2023 | Lorbrena, Braftovi, Mektovi |
| Gilead Sciences, INC. | $43.24 | 2021-2024 | Trodelvy |
| Mirati Therapeutics, INC. | $38.98 | 2023 | Krazati |
| Genentech USA, INC. | $37.32 | 2022 | |
| Aveo Pharmaceuticals, INC. | $34.51 | 2022-2023 | Fotivda |
| Celgene Corporation | $30.19 | 2022-2023 | Reblozyl |
| Lilly USA, LLC | $25.08 | 2023 | Retevmo, Jaypirca, Verzenio |
| Kyowa Kirin, INC. | $21.69 | 2023 | Poteligeo |
| Progenics Pharmaceuticals, INC. | $21.09 | 2023 | Pylarify |
| Sun Pharmaceutical Industries INC. | $20.38 | 2023 | Yonsa, Odomzo |
| Foundation Medicine, INC. | $15.78 | 2023 | |
| Spectrum Pharmaceuticals INC. | $15.63 | 2023 | Rolvedon |
| Kite Pharma, INC. | $15.35 | 2023 | |
| Taiho Oncology, INC. | $15.24 | 2023 | |
| Eisai INC. | $13.96 | 2022 | |
| G1 Therapeutics, INC. | $13.64 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $13.33 | 2023 | Monoferric |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Haluschak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.